A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce the ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...

SGLT-2I therapies reduce the risk of heart failure and this study clearly demonstrates the benefit of adding them onto ...

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist ...

CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

New research revealed that counseling interventions to increase walking and physical activity have reduced the risk of major ...

A study revealed that by following a fasting mimicking diet, you can reduce your risk of developing some chronic illnesses ...

While exercise is generally beneficial for a person's overall health, physical activities may increase the risk of adverse ...

The mixed, counterintuitive results hinder trial interpretation, but along with ARREST-AF, experts still see actionable ...

( MENAFN - GlobeNewsWire - Nasdaq) Stem Cell Therapy market Size Was Valued at USD 12.05 Billion in 2023, and is Projected to Reach USD 31.33 Billion by 2032, Growing at a CAGR of 11.20% From ...